Candel Therapeutics Stock (NASDAQ:CADL)
Previous Close
$8.35
52W Range
$4.35 - $9.57
50D Avg
$7.19
200D Avg
$5.83
Market Cap
$447.99M
Avg Vol (3M)
$1.82M
Beta
-0.48
Div Yield
-
CADL Company Profile
Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical firm based in Needham, Massachusetts, dedicated to developing innovative immunotherapies for cancer patients. Its pipeline features CAN-2409, which is presently in Phase II clinical trials for pancreatic and lung cancers, and has progressed to Phase III for prostate cancer. This therapy also successfully completed Phase Ib/II trials for high-grade glioma. Furthermore, the company is advancing CAN-3110, an investigational therapy currently in Phase I clinical trials for recurrent glioblastoma. Established in 2003, the company operated as Advantagene, Inc. until November 2020, when it rebranded as Candel Therapeutics, Inc.
CADL Performance
Peer Comparison
| Ticker | Company |
|---|---|
| CTNM | Contineum Therapeutics, Inc. Class A Common Stock |
| MREO | Mereo BioPharma Group plc |
| EDIT | Editas Medicine, Inc. |
| PRQR | ProQR Therapeutics N.V. |
| CAPR | Capricor Therapeutics, Inc. |
| CABA | Cabaletta Bio, Inc. |
| KYTX | Kyverna Therapeutics, Inc. |
| GNLX | Genelux Corporation |
| ALDX | Aldeyra Therapeutics, Inc. |
| IMMP | Immutep Limited |